Intrabronchial surfactant application in cases of inhalation injury: First results from patients with severe burns and ARDS

Burns

Volumn 24, Issue 3, 1998, Pages 197-206

  Pallua, Norbert ^a,b   Warbanow, Konstanze ^a,b   Noah, E M ^a,b   Machens, H G ^b   Poets, C ^b   Bernhard, W ^b   Berger, A ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute respiratory distress syndrome; Inhalation injury; Severe burn victims; Surfactant replacement

Indexed keywords

LUNG SURFACTANT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; BIOPHYSICS; CASE REPORT; CHEMICAL ANALYSIS; FEMALE; GAS EXCHANGE; HUMAN; HUMAN TISSUE; INJURY SCALE; LUNG BURN; LUNG COMPLIANCE; LUNG FUNCTION TEST; MALE; OXYGEN CONCENTRATION; RADIOLOGICAL PROCEDURES; SUBSTITUTION THERAPY; TISSUE OXYGENATION;

ADOLESCENT; ADULT; BRONCHI; BURNS, INHALATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSTILLATION, DRUG; MALE; MIDDLE AGED; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES;

EID: 0032078553     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(97)00112-5     Document Type: Article

References (45)

1. [1] Traber DL, Pollard V. Pathophysiology of inhalation injury. In: Herndon DN (Ed.) Total Burn Care 1996, W.B. Saunders, London. pp. 175-183
2. [2] Clark WR. Smoke inhalation: Diagnosis and treatment. World Journal of Surgery, 1992, 16: 24-29.
3. [3] Pallua N, de Buhr C, Berger A. Das pathogene Potential von Interleukin-6 und/ oder dessen Rezeptor bei der Entwicklung septischer Komplikationen nach Verbrennungstrauma In: Hierholzer G, Seifert J, Hartel W (Eds). Langenbecks Archiv für Chirurgie - Chirurgisches Forum 1995 für experimentelle und klinische Forschung. 1995 Springer, Berlin, Heidelberg.
4. [4] Shirani KZ, Pruitt BA, Mason AD. The influence of inhalation injury and pneumonia on burn mortality. Annals of Surgery 1987; 205 (1): 82-87.
5. [5] Bernhard W, Haagsman HP, Tschernig T, Poets CF, Postle AD, van Eijk ME, von der Hardt H. Conductive airway surfactant: surface tension function, biochemical composition, and possible alveolar origin. American Journal of Respiratory Cell and Molecular Biology 1997; Jul; 17(1): 41-50.
6. [6] Niemann GF, Clark WR, Wax SD, Webb WR. The effect of smoke inhalation on pulmonary surfactant. Annals of Surgery 1980; 191(2): 171-181.
7. [7] Gommers D, Lachmann B. Surfactant therapy: does it have a role in adults? Clinical Intensive Care 1993; 4: 284-295.
8. [8] Morgenroth K. Das Surfactantsystem der Lunge. Morphologische Grundlagen und klinische Bedeutung. 1986, Walter de Gruyter, Berlin, New York.
9. [9] Murray J, Matthay MA, Luce JM, Flick MR. Pulmonary perspectives. An expanded definition of the adult respiratory distress syndrome. American Review of Respiratory Disease 1988; 138(3): 720-723.
10. [10] Zellner PR, Lorenz S. Verbrennungskrankheit. In: Lawin P (Ed.) Praxis der Intensivbehandlung. 1994, Georg Thieme, Stuttgart, New York, pp. 1100-1109
11. [11] Lachmann B, Danzmann E. Adult respiratory distress syndrom. In: Robertson B, van Golde LMG, Batenburg JJ (Ed.) Pulmonary Surfactant. 1984, Elsevier, Amsterdam, New York, Oxford.
12. [12] Seeger W, Günther A, Walmrath HD, Grimminger F, Lasch HG. Alveolar surfactant and adult respiratory distress syndrome: Pathogenetic role and therapeutic prospects. Clinical Investigations 1993; 71: 177-190.
13. [13] Lawin P (Ed.). Praxis der Intensivbehandlung. 1994, Georg Thieme, Stuttgart, New York.
14. [14] Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. Conference Report. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes and clinical trial coordination. American Journal of Respiratory Critical Care in Medicine 1994; 149: 818-824.
15. [15] Surfactant-Update. Internationales Symposium. Aktuelle Aspekte und Entwicklungen. Hannover 12.05.95. Beilage zu Klinische Pädiatrie 1996; 208(1).
16. [16] Meek M, Munster AM, Winchurch RA,d Dicherson C. The Baltimore sepsis scale: Measurement of sepsis in patients with burns using a new scoring system. Journal of Burn Care Rehabilitation 1991; 12: 564-568.
17. [17] Pallua N, Machens H-G, Becker M, Berger A. Chirurgische Prävention der Posttraumatischen Sepsis durch Sofortnekrektomie von Verbrennungswunden. Langenbecks Archiv für Chirurgie 1996; 2(Suppl.): 144-148.
18. [18] Shelley SA, Paciga JE, Balis JU. Purification of surfactant from lung washings and washings contaminated with blood constituents. Lipids 1977; 12(6): 505-510.
19. [19] Raymonds K, Martin-Carrera I, Bernhard W, Poets C, von der Hardt H. A method for the isolation and preparation of surfactant from tracheobronchial aspirates in infants and children for quantitative and pulsating bubble analysis. European Journal of Clinical Investigation 1996; 26: 983-988.
20. [20] Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP, Milligan J. Prevention of respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics 1985; 76: 145-153.
21. [21] Knaus W, Sun X, Hakim R, Wagner D. Evaluation of definitions for adult respiratory distress syndrome. American Journal of Respiratory Critical Care in Medicine 1994; 10: 311-317.
22. [22] Stubbig K, Schmidt H, Böhrer H, Huster Th. Bach A, Motsch, J. Surfactantapplikation bei akutem Lungenversagen. Anaesthesist 1992; 41: 555-558.
23. [23] Joka Th., Obertacke U. Neue medikamentöse Behandlung im ARDS: Effekt einer intrabronchialen xenogenen Surfactantapplikation, Zeitschnift für Herz, Thorax, Gefäßchir 1989; 3(Suppl. 1): 21-24.
24. [24] Schlitt HJ, Werner U, Schandelmaier P, Krettek C, Dreinhöfer K, Hauss J, Pichlmayr R. Posttraumatisches akutes lungenversagen. Behandlung durch drucklimitierte beatmung und kontinuierlichen lagewechsel. Deutsch medizinische Wochenschrift 1991; 116: 1257-1264.
25. [25] Seeger W, Grube C, Günther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. European Respiratory Journal 1993; 6: 971-977.
26. [26] Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2: 319-323.
27. [27] Petty TL, Ashbaugh DG. The adult respiratory distress syndrome: Clinical features, factors influencing prognosis and principles of management. Chest 1971; 60: 233-239.
28. [28] Wauer RR. Das Atemnotsyndrom (ANS). In: Wauer RR (Ed.) Surfactant Therapie des Neonatalen Atemnotsyndroms. 1993, Georg Thieme, Stuttgart, New York, pp. 1-16.
29. [29] Ebbecke K, Blanke JG, Brehmer U, Jorch G. Surfactanttherapie bei schwerer neonataler Ateminsuffizienz. Multizentrische studie. Klinische Pädiatrie 1993; 205: 71-82.
30. [30] Lachmann B. Is there a future for surfactant replacement therapy in the adult respiratory distress syndrome?. Intensive Care 1987; 2: 1-6.
31. [31] Rossaint R, Pappert D, Gerlach H, Falke K. Therapy of ARDS. 2. New management methods - first clinical experiences. Anaesthesist 1994; 43(6): 364-375.
32. [32] Seeger W, Walmrath D, Grimminger F. ARDS: Intensivtherapie des akuten Lungenversagens. Internist 1995; 36: 785-801.
33. [33] Lachmann B. Animal models and clinical pilot studies of surfactant replacement in adult respiratory distress syndrome. European Respiratory Journal 1989; 2: 98
34. [34] Lewis JF, Tabor B, Ikegami M, Jobe AH, Joseph M, Absolom D. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs nebulized surfactant. Journal of Applied Physiology 1993; 74(3): 1256-1264.
35. [35] Bardenheuer M, Dresing K, Obertacke U. Komplizierter Verlauf nach Lungenkontusion beim Kind. Ist die Surfactantgabe indiziert? Zentralblatt für Kinderchirurgie 1993; 2: 157-161.
36. [36] Möller JC, Reiss I, Schaible Th. Tegtmeyer FK, Gortner L. Surfactantbehandlung des respiratorischen Versagens im Kindesalter jenseits der Neugeborenenperiode. Monatsschrift Kinderheilkunde 1995; 143: 685-690.
37. [37] Pallua N, Warbanow K, Machens H-G, Poets C, Berger A, Intrabronchiale Surfactantapplikation bei inhalationstraumatisierten Schwerbrandverletzten mit ARDS - Erste Fallberichte. Unfallchirurg 1997; 100: 363-370.
38. [38] Poets CF, Arning A, Bernhard W, Acevedo C, von der Hardt H. Active surfactantin pharyngeal aspirates of term neonates: lipid biochemistry and surface tension function. European Journal of Clinical Investigations 1997; 27(4): 293-298.
39. [39] Wauer RR. Das atemnotsyndrom (ANS) - Epidemiologie, Pathophysiologie, Klinik und Prinzipien der Surfactanttherapie. In: Wauer RR (Ed.) Surfactant Therapie - Grundlagen, Diagnostik, Therapie. 1997, Georg Thieme, Stuttgart, New York, pp. 2-20.
40. [40] Fuchimukai T, Fujiwara T, Takahashi A, Enhorning G. Artificial pulmonary surfactant inhibited by proteins. Journal of Applied Physiology 1987; 62(2): 429-437.
41. [41] Seeger W, Walmrath D, Günther A, Schmidt R, Nix F, Yabut M, Schermuly R, Grimminger F. Improvement of biochemical and biophysical surfactant properties upon bronchoscopic surfactant administration in ARDS. American Journal of Critical Care in Medicine 1995; 151(4): A77
42. [42] Enhorning G. Pulsating bubble technique for evaluating pulmonary surfactant. Journal of Applied Physiology 1977; 43: 198-203.
43. [43] Gortner L, Bartmann P, Pohlandt F, Bernsau U, Porz F, Hellwege HH, Seitz RC, Hieronimi G, Bremer C, Jorch G, Hentschel R, Reiter HL, Wolf H, Ball F. Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: A multicenter controlled clinical trial. Pediatrics and Pulmonology 1992; 14: 4-9.
44. [44] Tobiasen J, Hiebert JM, Edlich RF. The abbreviated burn severity index. Annals of Emergency Medicine 1982; 11(5): 260-262.
45. [45] Webster NR, Cohen AT, Nunn JF. Adult respiratory distress syndrome - how many cases in the UK? Anaesthesia 1988; 43(11): 923-926.